Children: prednisolone showed no clear difference in admission at initial presentation compared with dexamethasone (low certainty).
Children: prednisolone showed no clear difference in re‐admission during compared with dexamethasone (low certainty).
Children: prednisolone showed no clear difference in new exacerbation during compared with dexamethasone (low certainty).
Cyclosporin plus prednisolone may leads to lower relapse at 6 months compared with prednisolone alone (low certainty).
Cyclosporin plus prednisolone showed no clear difference in relapse at 12 months compared with prednisolone alone (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether cyclosporin plus prednisolone changes adverse effects: number needing cytotoxic agents compared with prednisolone alone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).